  0 Table of Contents |
  1 Home |
| 2 Background |
 3 Artifacts Summary |
 3.1 ICR Campaign — target geography |
| 3.2 ICR Location — catchment of |
| 3.3 ICR Location — H3 cell |
| 3.4 ICR Location — quadkey cell |
| 3.5 ICR Target Population — geography |
| 3.6 ICR Administrative Coverage Measure |
| 3.7 ICR Campaign Cost Measure |
| 3.8 ICR Campaign Readiness Measure |
| 3.9 ICR Geographic Coverage Measure |
| 3.10 ICR Household Coverage Measure |
| 3.11 ICR MDA Treatment Coverage Measure |
| 3.12 ICR Survey Coverage Measure |
| 3.13 ICR Zero-dose Coverage Measure |
| 3.14 ICR Campaign Readiness Checklist |
| 3.15 ICR MDA Supervision Checklist |
| 3.16 ICR Administrative Coverage |
| 3.17 ICR Adverse Event |
| 3.18 ICR Campaign |
| 3.19 ICR Campaign Activity |
| 3.20 ICR Campaign Cost |
| 3.21 ICR Campaign Form Response |
| 3.22 ICR Campaign Protocol |
| 3.23 ICR Campaign Task |
| 3.24 ICR Care Team |
| 3.25 ICR Consent (Person-Data Governance) |
| 3.26 ICR Cost Report |
| 3.27 ICR Delivery Unit (Household / Community / School Cohort) |
| 3.28 ICR Facility Organization |
| 3.29 ICR Immunization Event |
| 3.30 ICR Location |
| 3.31 ICR Location Status |
| 3.32 ICR Medication Administration |
| 3.33 ICR Patient (Beneficiary / Registered Individual) |
| 3.34 ICR Referral |
| 3.35 ICR Referral Fulfilment |
| 3.36 ICR Resource Estimate |
| 3.37 ICR Stock Count |
| 3.38 ICR Supply Distribution |
| 3.39 ICR Supply Movement |
| 3.40 ICR Survey Coverage |
| 3.41 ICR Target Population |
| 3.42 Building Count |
| 3.43 Campaign |
| 3.44 Campaign Activity |
| 3.45 Campaign Round |
| 3.46 Catchment Of |
| 3.47 Confidence Interval |
| 3.48 Cost Allocation |
| 3.49 Cost Lineage |
| 3.50 Cost Perspective |
| 3.51 Cost Scope |
| 3.52 Coverage Source |
| 3.53 Coverage Unit |
| 3.54 Delivery Strategy |
| 3.55 Denominator Source |
| 3.56 Denominator Type |
| 3.57 DHIS2 Indicator |
| 3.58 DHIS2 Period |
| 3.59 Directly Observed Consumption |
| 3.60 Distribution Recipient |
| 3.61 Dose-pole Band |
| 3.62 Estimate Basis |
| 3.63 Estimate Confidence |
| 3.64 Estimate Date |
| 3.65 Evaluated Resource Role |
| 3.66 Funding Source |
| 3.67 Group Location |
| 3.68 Is Calculated |
| 3.69 Is Planning Denominator |
| 3.70 Issued To Team |
| 3.71 Location Boundary (GeoJSON) |
| 3.72 Oversees Area |
| 3.73 Planning Denominator |
| 3.74 Prior-dose Status (Zero-dose) |
| 3.75 Real-time vs Reconciled |
| 3.76 Record Origin |
| 3.77 Referring Task |
| 3.78 Relationship to Head of Household |
| 3.79 Report Source |
| 3.80 Reporter Team |
| 3.81 Sample Design |
| 3.82 Serious-Event Criteria |
| 3.83 Settlement / Special-population Type |
| 3.84 Social Mobilization |
| 3.85 Spatial Index Cell |
| 3.86 Stock Accountability |
| 3.87 Stock Count Basis |
| 3.88 Supplied Item |
| 3.89 Target Geography |
| 3.90 Task Origin |
| 3.91 Unit of Count |
| 3.92 Workload Target |
| 3.93 ICR Adverse Event Causality |
| 3.94 ICR Adverse Event Seriousness |
| 3.95 ICR Building Footprint Source |
| 3.96 ICR Campaign Type |
| 3.97 ICR Communication Channel |
| 3.98 ICR Cost Allocation Basis |
| 3.99 ICR Cost Category |
| 3.100 ICR Cost Figure |
| 3.101 ICR Cost Lineage |
| 3.102 ICR Cost Perspective |
| 3.103 ICR Cost Scope |
| 3.104 ICR Count Unit |
| 3.105 ICR Coverage Source |
| 3.106 ICR Coverage Stratifier |
| 3.107 ICR Coverage Unit |
| 3.108 ICR Data Lineage |
| 3.109 ICR Delivery Strategy |
| 3.110 ICR Denominator Source |
| 3.111 ICR Denominator Type |
| 3.112 ICR Dose History / Zero-dose Status |
| 3.113 ICR Endemicity Status |
| 3.114 ICR Exclusion Reason |
| 3.115 ICR Facility Ownership |
| 3.116 ICR Facility Type |
| 3.117 ICR Funding Source |
| 3.118 ICR Group Kind |
| 3.119 ICR Independent Coverage Source |
| 3.120 ICR Location Status |
| 3.121 ICR Location Type |
| 3.122 ICR MDA Medication |
| 3.123 ICR MDA Medicine Package |
| 3.124 ICR Missed Reason |
| 3.125 ICR Not-done Reason |
| 3.126 ICR NTD Disease |
| 3.127 ICR Record Origin |
| 3.128 ICR Referral Reason |
| 3.129 ICR Refusal Reason |
| 3.130 ICR Relationship to Head of Household |
| 3.131 ICR Report Source |
| 3.132 ICR Resource Type |
| 3.133 ICR Revisit Outcome |
| 3.134 ICR Serious-Event Criteria |
| 3.135 ICR Settlement / Special-population Type |
| 3.136 ICR Spatial Index Scheme |
| 3.137 ICR Supplied Item |
| 3.138 ICR Task Input Type |
| 3.139 ICR Task Origin |
| 3.140 ICR Task Output Type |
| 3.141 ICR Team Role |
| 3.142 ICR Travel Time Band |
| 3.143 ICR Adverse Event Causality |
| 3.144 ICR Building Footprint Source |
| 3.145 ICR Campaign Type |
| 3.146 ICR Commodity Class |
| 3.147 ICR Communication Channel |
| 3.148 ICR Cost Allocation Basis |
| 3.149 ICR Cost Category |
| 3.150 ICR Cost Component |
| 3.151 ICR Cost Figure |
| 3.152 ICR Cost Lineage |
| 3.153 ICR Cost Perspective |
| 3.154 ICR Cost Scope |
| 3.155 ICR Count Unit |
| 3.156 ICR Coverage Group |
| 3.157 ICR Coverage Source |
| 3.158 ICR Coverage Stratifier |
| 3.159 ICR Coverage Unit |
| 3.160 ICR Data Lineage |
| 3.161 ICR Delivery Strategy |
| 3.162 ICR Denominator Source |
| 3.163 ICR Denominator Type |
| 3.164 ICR Dose History / Zero-dose Status |
| 3.165 ICR Endemicity Status |
| 3.166 ICR Exclusion Reason |
| 3.167 ICR Facility Ownership |
| 3.168 ICR Facility Type |
| 3.169 ICR Funding Source |
| 3.170 ICR Group Characteristic |
| 3.171 ICR Group Kind |
| 3.172 ICR Household Relationship |
| 3.173 ICR Identifier Type |
| 3.174 ICR Location Status |
| 3.175 ICR Location Type |
| 3.176 ICR MDA Medicine Package |
| 3.177 ICR Missed Reason |
| 3.178 ICR NTD Disease |
| 3.179 ICR Project Tag |
| 3.180 ICR Record Origin |
| 3.181 ICR Referral Category |
| 3.182 ICR Referral Reason |
| 3.183 ICR Refusal Reason |
| 3.184 ICR Report Source |
| 3.185 ICR Resource Type |
| 3.186 ICR Revisit Outcome |
| 3.187 ICR Serious-Event Criteria |
| 3.188 ICR Settlement / Special-population Type |
| 3.189 ICR Spatial Index Scheme |
| 3.190 ICR Stock Observation Code |
| 3.191 ICR Task Input Type |
| 3.192 ICR Task Origin |
| 3.193 ICR Task Output Type |
| 3.194 ICR Team Role |
| 3.195 ICR Travel Time Band |
| 3.196 ICR Referral Reason to SNOMED CT |
| 3.197 ICR ↔ WHO IMMZ AEFI Causality |
| 3.198 Administer albendazole — MDA activity definition |
| 3.199 Administer MCV — campaign activity definition |
| 3.200 Administer nOPV2 — campaign activity definition |
| 3.201 Administer praziquantel — SCH MDA activity definition |
| 3.202 Administrative coverage — Kambia MR SIA, June 2026 round |
| 3.203 Administrative coverage — nOPV2 in the Kambia integrated round, September 2026 |
| 3.204 Adverse event — abdominal pain following albendazole |
| 3.205 AEFI — anaphylaxis following MCV dose (serious) |
| 3.206 AEFI — fever following MCV dose |
| 3.207 Albendazole administration — MDA register entry |
| 3.208 Albendazole issue — CDD team 7, day 1 (field-team daily stock) |
| 3.209 Albendazole not given — excluded for acute illness |
| 3.210 Albendazole receipt — Rokupr community (ATC-coded drug supply) |
| 3.211 Campaign readiness roll-up — Kambia, pre-campaign validation |
| 3.212 Care team — CDD team 7, Rokupr |
| 3.213 Community-directed MDA — Rokupr, albendazole round |
| 3.214 Cost line — MR vaccine, national procurement (actual, umbrella campaign) |
| 3.215 Cost line — transport & fuel, Kambia round (actual) |
| 3.216 Cost line — vaccinator per diems, Kambia round (actual) |
| 3.217 Cost line — vaccinator per diems, Kambia round (budgeted) |
| 3.218 Cost report — Kambia MR SIA, June 2026 round (actual · financial · delivery-only) |
| 3.219 Cost report — Kambia MR SIA, June 2026 round (actual · financial · full · fully-loaded) |
| 3.220 Distribute ITNs — activity definition |
| 3.221 ESPEN MDA — 1. Location Registration Form |
| 3.222 ESPEN MDA — 2. Medicine Receipt Form |
| 3.223 ESPEN MDA — 3. Medicine Treatment Form (tally) |
| 3.224 ESPEN MDA — 4. Medicine Use & Case Management Form |
| 3.225 ESPEN MDA — 5. Supervision: Health Facility |
| 3.226 ESPEN MDA — 6. Supervision: CDD Observation |
| 3.227 Example Child |
| 3.228 Example Co-head of Household |
| 3.229 Example Community — Rokupr |
| 3.230 Example Consent — registry data sharing |
| 3.231 Example Country |
| 3.232 Example District |
| 3.233 Example Dwelling |
| 3.234 Example Facility Organization — Rokupr CHC |
| 3.235 Example Facility — Rokupr CHC (place) |
| 3.236 Example Fixed Post — Rokupr CHC |
| 3.237 Example Head of Household |
| 3.238 Example Household |
| 3.239 Example Household — fully enumerated |
| 3.240 Example School Cohort — Rokupr Primary School |
| 3.241 Example School — Rokupr Primary School |
| 3.242 Example Settlement |
| 3.243 Example Sibling |
| 3.244 Example Supervisory Area |
| 3.245 Example Target Population — at-risk population, Rokupr community (STH MDA) |
| 3.246 Example Target Population — children 0–14 years, Kambia District |
| 3.247 Example Target Population — children 0–59 months, Kambia District |
| 3.248 Example Target Population — children 9m–14y, Kambia District |
| 3.249 Example Target Population — children 9m–14y, Kambia District (enumeration estimate) |
| 3.250 Example Target Population — children 9m–14y, Kambia District (sum of ward microplan estimates, calculated) |
| 3.251 Example Target Population — children 9m–14y, Rokupr CHC catchment |
| 3.252 Example Target Population — children 9m–14y, Sierra Leone (national) |
| 3.253 Example Target Population — households registered, Rokupr (ITN 2026 enumeration) |
| 3.254 Example Target Population — households, Rokupr (ITN 2026) |
| 3.255 Example Target Population — population protected, Rokupr IRS |
| 3.256 Example Target Population — school-aged children 5–14, Kambia District (descoped round) |
| 3.257 Example Ward — national DHIS2 code only |
| 3.258 Follow-up revisit — missed child, Rokupr block 4 |
| 3.259 Geographic coverage — Kambia MDA (villages treated / total) |
| 3.260 Household coverage — ITN Rokupr, August 2026 |
| 3.261 Integrated household visit — MR and nOPV2, Rokupr block 4, house 12 |
| 3.262 Integrated MR + nOPV2 protocol |
| 3.263 IRS protocol — annual indoor residual spraying |
| 3.264 IRS Rokupr — 2026 annual round |
| 3.265 IRS structure visit — Rokupr block 4, house 12 |
| 3.266 ITN distribution redeeming voucher RKP-0412 |
| 3.267 ITN distribution to household |
| 3.268 ITN mass distribution protocol — registration then distribution |
| 3.269 ITN mass distribution, Rokupr — August 2026 |
| 3.270 ITN registration visit — Rokupr block 4, house 12 |
| 3.271 Kambia integrated MR + nOPV2 — September 2026 |
| 3.272 Kambia MR SIA — June 2026 round |
| 3.273 Kambia SCH MDA 2026 — descoped round (SAC only, supply-constrained) |
| 3.274 LF endemicity — Kambia District (endemic, under MDA) |
| 3.275 LQAS lot assessment — Kambia MR SIA, June 2026 round |
| 3.276 MCV dose — campaign record |
| 3.277 MDA treatment coverage — Rokupr albendazole round (sex × age stratified) |
| 3.278 Measles–Rubella SIA Protocol |
| 3.279 Mop-up household visit — Rokupr block 4, house 12 |
| 3.280 MR eligible population — children 9 months–14 years (definitional) |
| 3.281 nOPV2 eligible population — children 0–59 months (definitional) |
| 3.282 Onchocerciasis endemicity — Kambia District (non-endemic) |
| 3.283 Post-campaign survey coverage — Kambia MR SIA, June 2026 round |
| 3.284 Readiness validation — Kambia supervision zone 2 |
| 3.285 Referral created from a facility record — fever, Rokupr CHC |
| 3.286 Referral fulfilment — facility record HFR-0042, Rokupr CHC |
| 3.287 Referral fulfilment — zero-dose child seen at Rokupr CHC |
| 3.288 Referral — zero-dose child to routine immunization, Rokupr CHC |
| 3.289 Register households — ITN activity definition |
| 3.290 Resource estimate — LLINs for Rokupr (ITN 2026 microplan) |
| 3.291 Schistosomiasis MDA protocol — national policy: everyone 2+ |
| 3.292 School session — praziquantel MDA at Rokupr Primary School |
| 3.293 Sierra Leone MR SIA 2026 — national umbrella campaign |
| 3.294 Site session — Rokupr CHC fixed post, campaign day 3 |
| 3.295 Spray structure — IRS activity definition |
| 3.296 STH MDA eligible population — school-age children 5–14 years (definitional) |
| 3.297 STH MDA protocol — albendazole, community-directed |
| 3.298 STH MDA, Rokupr community — February 2026 round |
| 3.299 Stock count — albendazole, Rokupr staging point, after the February 2026 round |
| 3.300 Supervision report — CDD observation, Rokupr |
| 3.301 Zero-dose reach — Kambia MR SIA, June 2026 round |
| 3.302 ICR campaign activities |
| 3.303 ICR campaign calendar |
| 3.304 ICR campaign task tallies per activity |
| 3.305 ICR campaign tasks |
| 3.306 ICR coverage reports |
| 3.307 ICR coverage strata |
| 3.308 ICR indicator groups |
| 3.309 ICR indicator strata |
| 3.310 ICR indicator values |
| 3.311 ICR indicators |
| 3.312 ICR location status |
 3.313 ICR target populations |
